BACKGROUND: Histone deacetylase (HDAC) is well known to be associated with tumorigenesis through epigenetic regulation, and its inhibitors (HDACIs) induce differentiation and apoptosis of tumor cells. We examined the therapeutic effects of valproic acid (VPA, a HDACI) with a combination of 5-fluorouracil (5-FU) in vitro. METHODS: A human pancreas cancer cell line (SUIT-2) and a cholangiocarcinoma cell line (HuCCT1) were used. Cell viabilities were evaluated by a cell proliferation assay. We determined the anticancer effects of VPA combined with 5-FU in these cell lines. RESULTS: Pancreas cancer (SUIT-2): No effect of 5-FU (1.0 µM) was observed, but 17% and 30% of proliferation-inhibitory effects were recognized in a dose of 2.5 or 5.0 µM, respectively. Cell viability was only weakly reduced by VPA (0.5 mM). However, in combination of 5-FU (1.0 µM) with VPA (0.5 mM), 19% of inhibitory effect was observed. Cholangiocarcinoma (HuCCT1): 5-FU (1.0 µM) did not suppress the cell viability, but 5-FU (2.5 µM) suppressed by 23%. VPA (0.5 mM) did not suppress the cell viability, while VPA (1.0 mM) weakly decreased it by 11%. Combination of 5-FU (1.0 µM) and VPA (0.5 mM) markedly reduced the cell viability by 30%. CONCLUSION: VPA augmented the anti-tumor effects of 5-FU in cancer cell lines. Therefore, a combination therapy of 5-FU plus VPA may be a promising therapeutic option for patients with pancreas cancer and cholangiocarcinoma.
BACKGROUND:Histone deacetylase (HDAC) is well known to be associated with tumorigenesis through epigenetic regulation, and its inhibitors (HDACIs) induce differentiation and apoptosis of tumor cells. We examined the therapeutic effects of valproic acid (VPA, a HDACI) with a combination of 5-fluorouracil (5-FU) in vitro. METHODS: A humanpancreas cancer cell line (SUIT-2) and a cholangiocarcinoma cell line (HuCCT1) were used. Cell viabilities were evaluated by a cell proliferation assay. We determined the anticancer effects of VPA combined with 5-FU in these cell lines. RESULTS:Pancreas cancer (SUIT-2): No effect of 5-FU (1.0 µM) was observed, but 17% and 30% of proliferation-inhibitory effects were recognized in a dose of 2.5 or 5.0 µM, respectively. Cell viability was only weakly reduced by VPA (0.5 mM). However, in combination of 5-FU (1.0 µM) with VPA (0.5 mM), 19% of inhibitory effect was observed. Cholangiocarcinoma (HuCCT1): 5-FU (1.0 µM) did not suppress the cell viability, but 5-FU (2.5 µM) suppressed by 23%. VPA (0.5 mM) did not suppress the cell viability, while VPA (1.0 mM) weakly decreased it by 11%. Combination of 5-FU (1.0 µM) and VPA (0.5 mM) markedly reduced the cell viability by 30%. CONCLUSION:VPA augmented the anti-tumor effects of 5-FU in cancer cell lines. Therefore, a combination therapy of 5-FU plus VPA may be a promising therapeutic option for patients with pancreas cancer and cholangiocarcinoma.
Authors: James L Chen; Tanios Bekaii-Saab; Daniel H Ahn; Milind Javle; Chul W Ahn; Apurva Jain; Sameh Mikhail; Anne M Noonan; Kristen Ciombor; Christina Wu; Rachna T Shroff Journal: Cancer Date: 2016-08-06 Impact factor: 6.860
Authors: M Nikbakht Dastjerdi; M R Salahshoor; M Mardani; M Rabbani; B Hashemibeni; M Gharagozloo; M Kazemi; N Esmaeil; Sh Roshankhah; R Golmohammadi; M Mobarakian Journal: Res Pharm Sci Date: 2013-04
Authors: Olivier Peulen; Arnaud Gonzalez; Paul Peixoto; Andrei Turtoi; Denis Mottet; Philippe Delvenne; Vincent Castronovo Journal: PLoS One Date: 2013-09-11 Impact factor: 3.240
Authors: Mohammad Reza Salahshoor; Mehdi Nikbakht Dastjerdi; Cyrus Jalili; Mohammad Mardani; Mozafar Khazaei; Ahmad Shabanizadeh Darehdor; Ali Valiani; Shiva Roshankhah Journal: Int J Prev Med Date: 2013-12